miR-342 Regulates BRCA1 expression through modulation of ID4 in breast cancer

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Crippa, Elisabetta ^a,b   Lusa, Lara ^a,b,c   De Cecco, Loris ^a,b   Marchesi, Edoardo ^a,b   Calin, George Adrian ^d   Radice, Paolo ^a,b   Manoukian, Siranoush ^a   Peissel, Bernard ^a   Daidone, Maria Grazia ^a   Gariboldi, Manuela ^a,b   Pierotti, Marco Alessandro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; MICRORNA; MICRORNA 342; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; ID4 GENE; IN VITRO STUDY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; ONCOGENE; PROTEIN FUNCTION;

BLOTTING, WESTERN; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEINS; LUCIFERASES; MICROARRAY ANALYSIS; MICRORNAS; PLASMIDS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 84899958553     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087039     Document Type: Article

References (48)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
2. Bradbury AR, Olopade OI (2007) Genetic susceptibility to breast cancer. Reviews in endocrine & metabolic disorders 8: 255-267. (Pubitemid 47524871)
3. Lacroix M, Leclercq G (2005) The "portrait" of hereditary breast cancer. Breast cancer research and treatment 89: 297-304.
4. Ahmed M, Lalloo F, Evans DG (2009) Update on genetic predisposition to breast cancer. Expert review of anticancer therapy 9: 1103-1113.
5. Da Silva L, Lakhani SR (2010) Pathology of hereditary breast cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 23 Suppl 2: S46-51.
6. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M (2010) Genetic susceptibility to breast cancer. Molecular oncology 4: 174-191.
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-838. (Pubitemid 40839735)
8. Kim VN, Nam JW (2006) Genomics of microRNA. Trends in genetics : TIG 22: 165-173.
9. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America 103: 2257-2261. (Pubitemid 43271657)
10. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
11. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nature reviews Cancer 6: 857-866. (Pubitemid 44629897)
12. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer research 65: 7065-7070. (Pubitemid 41161233)
13. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, et al. (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome biology 8: R214.
14. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, et al. (2009) MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast cancer research : BCR 11: R27.
15. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, et al. (2011) microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer research 71: 5635-5645.
16. O'day E, Lal A (2010) MicroRNAs and their target gene networks in breast cancer. Breast Cancer Research 12.
17. Manoukian S, Peissel B, Pensotti V, Barile M, Cortesi L, et al. (2007) Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. European Journal of Cancer 43: 601-606. (Pubitemid 46177595)
18. Piffanelli A, Giovannini G, Pelizzola D, De Bortoli M, Catozzi L, et al. (1991) Steroid receptor assays: an Italian quality assessment program. Annali dell'Istituto superiore di sanita 27: 523-529.
19. Ronchi E, Granata G, Brivio M, Coradini D, Miodini P, et al. (1986) A double-labeling assay for simultaneous estimation and characterization of estrogen and progesterone receptors using radioiodinated estradiol and tritiated Org 2058. Tumori 72: 251-257. (Pubitemid 17190690)
20. Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, et al. (2004) An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proceedings of the National Academy of Sciences of the United States of America 101: 9740-9744. (Pubitemid 38869306)
21. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, et al. (2002) Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic acids research 30: e15.
22. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
23. Dell'Orso S, Ganci F, Strano S, Blandino G, Fontemaggi G (2010) ID4: a new player in the cancer arena. Oncotarget 1: 48-58.
24. de Candia P, Akram M, Benezra R, Brogi E (2006) Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma. Human pathology 37: 1032-1041. (Pubitemid 44080809)
25. Beger C, Pierce LN, Kruger M, Marcusson EG, Robbins JM, et al. (2001) Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proceedings of the National Academy of Sciences of the United States of America 98: 130-135. (Pubitemid 32095875)
26. Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, et al. (1998) Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer research 58: 3237-3242. (Pubitemid 28371058)
27. Roldan G, Delgado L, Muse IM (2006) Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer. Cancer biology & therapy 5: 505-510. (Pubitemid 43765285)
28. De Marchis ML, Ballarino M, Salvatori B, Puzzolo MC, Bozzoni I, et al. (2009) A new molecular network comprising PU.1, interferon regulatory factor proteins and miR-342 stimulates ATRA-mediated granulocytic differentiation of acute promyelocytic leukemia cells. Leukemia 23: 856-862.
29. Wang H, Wu J, Meng X, Ying X, Zuo Y, et al. (2011) MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis 32: 1033-1042.
30. Grady WM, Parkin RK, Mitchell PS, Lee JH, Kim YH, et al. (2008) Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 27: 3880-3888. (Pubitemid 351862055)
31. Van der Auwera I, Limame R, van Dam P, Vermeulen PB, Dirix LY, et al. (2010) Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. British journal of cancer 103: 532-541.
32. Savad S, Mehdipour P, Miryounesi M, Shirkoohi R, Fereidooni F, et al. (2012) Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran. Asian Pacific journal of cancer prevention : APJCP 13: 873-877.
33. He YJ, Wu JZ, Ji MH, Ma T, Qiao EQ, et al. (2013) miR-342 is associated with estrogen receptor-alpha expression and response to tamoxifen in breast cancer. Experimental and therapeutic medicine 5: 813-818.
34. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, et al. (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. The Journal of biological chemistry 283: 29897-29903.
35. Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, et al. (2010) Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Molecular Cancer 9.
36. Perk J, Iavarone A, Benezra R (2005) ID family of helix-loop-helix proteins in cancer (vol 5, pg 603, 2005). Nature Reviews Cancer 5.
37. Kamalian L, Gosney JR, Forootan SS, Foster CS, Bao ZZ, et al. (2008) Increased expression of Id family proteins in small cell lung cancer and its prognostic significance. Clinical Cancer Research 14: 2318-2325. (Pubitemid 351551063)
38. Zeng W, Rushing EJ, Hartmann DP, Azumi N (2010) Increased inhibitor of differentiation 4 (id4) expression in glioblastoma: a tissue microarray study. Journal of Cancer 1: 1-5.
39. Venneti S, Le P, Martinez D, Xie SX, Sullivan LM, et al. (2011) Malignant Rhabdoid Tumors Express Stem Cell Factors, Which Relate To the Expression of EZH2 and Id Proteins. American Journal of Surgical Pathology 35: 1463-1472.
40. Lasorella A, Uo T, Iavarone A (2001) Id proteins at the cross-road of development and cancer. Oncogene 20: 8326-8333. (Pubitemid 34121903)
41. Jen Y, Manova K, Benezra R (1996) Expression patterns of Id1, Id2, and Id3 are highly related but distinct from that of Id4 during mouse embryogenesis. Developmental Dynamics 207: 235-252. (Pubitemid 26378326)
42. Kuzontkoski PM, Mulligan-Kehoe MJ, Harris BT, Israel MA (2010) Inhibitor of DNA binding-4 promotes angiogenesis and growth of glioblastoma multiforme by elevating matrix GLA levels. Oncogene 29: 3793-3802.
43. Park SJ, Kim RJ, Nam JS (2011) Inhibitor of DNA-binding 4 contributes to the maintenance and expansion of cancer stem cells in 4T1 mouse mammary cancer cell line. Laboratory animal research 27: 333-338.
44. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, et al. (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26: 2126-2132. (Pubitemid 46514749)
45. Wen YH, Ho A, Patil S, Akram M, Catalano J, et al. (2012) Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. Breast cancer research and treatment 135: 93-102.
46. Heyn H, Engelmann M, Schreek S, Ahrens P, Lehmann U, et al. (2011) MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. International Journal of Cancer 129: 2797-2806.
47. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527. (Pubitemid 44854747)
48. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, et al. (2009) Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery. Plos One 4.